Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children

Maria Rosario Capeding, Samuel Teshome, Tarun Saluja, Khalid Ali Syed, Deok Ryun Kim, Ju Yeon Park, Jae Seung Yang, Yang Hee Kim, Jiwook Park, Sue-Kyoung Jo, Yun Chon, Sudeep Kothari, Seon-Young Yang, Dong Soo Ham, Ji Hwa Ryu, Hee-Seong Hwang, Ju-Hwan Mun, Julia A Lynch, Jerome H Kim, Hun Kim, Jean-Louis Excler, Sushant Sahastrabuddhe, Maria Rosario Capeding, Samuel Teshome, Tarun Saluja, Khalid Ali Syed, Deok Ryun Kim, Ju Yeon Park, Jae Seung Yang, Yang Hee Kim, Jiwook Park, Sue-Kyoung Jo, Yun Chon, Sudeep Kothari, Seon-Young Yang, Dong Soo Ham, Ji Hwa Ryu, Hee-Seong Hwang, Ju-Hwan Mun, Julia A Lynch, Jerome H Kim, Hun Kim, Jean-Louis Excler, Sushant Sahastrabuddhe

Abstract

Background: Typhoid fever remains a major public health problem in low- and middle-income countries where children aged 2-14 years bear the greatest burden. Vi polysaccharide is poorly immunogenic in children <2 years of age, and protection in adults is modest. The limitations of Vi polysaccharide vaccines can be overcome by conjugation of the Vi to a carrier protein. A typhoid conjugate vaccine composed of Vi polysaccharide conjugated to diphtheria toxoid (Vi-DT) has been developed. The Phase I study results are presented here.

Methods: This was a randomized, observer-blinded Phase I study to assess the safety and immunogenicity of Vi-DT compared to Vi polysaccharide vaccine, conducted in Manila, Philippines. Participants enrolled in an age de-escalation manner (18-45, 6-17 and 2-5 years) were randomized between Test (Vi-DT, 25 µg) administered at 0 and 4 weeks and Comparator (Vi polysaccharide, Typhim Vi® and Vaxigrip®, Sanofi Pasteur) vaccines.

Results: A total of 144 participants were enrolled (48 by age strata, 24 in Test and Comparator groups each). No serious adverse event was reported in either group. Solicited and unsolicited adverse events were mild or moderate in both groups with the exception of a 4-year old girl in Test group with grade 3 fever which resolved without sequelae. All participants in Test group seroconverted after first and second doses of Vi-DT while the proportions in the Comparator group were 97.1% and 97.2%, after first dose of Typhim Vi® and second dose of Vaxigrip®, respectively. Vi-DT showed 4-fold higher Geometric Mean Titers (GMT) compared to Typhim Vi® (adjusted for age strata, p < 0.001). No further increase of GMT was detected after the second dose of Vi-DT. Anti-DT IgG seroresponse rates were 81.2% and 84.5% post first and second Vi-DT doses, respectively.

Conclusions: Vi-DT vaccine was safe, well-tolerated and immunogenic in participants aged 2-45 years. ClinicalTrials.gov registration number: NCT02645032.

Keywords: Conjugate vaccine; Immunogenicity; Safety; The Philippines; Typhoid; Vi-DT.

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Flow diagram of participant disposition (CONSORT flow diagram) by analysis sets.
Fig. 2
Fig. 2
Anti-Vi serum IgG ELISA antibody response (titers in μg/mL) by Age group.

References

    1. Background paper on typhoid vaccines for SAGE meeting [October 2017]. .
    1. Antillón M., Bilcke J., Paltiel A.D., Pitzer V.E. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 2017;35:3506–3514.
    1. Bhutta Z.A. Impact of age and drug resistance on mortality in typhoid fever. Arch Dis Child. 1996;75:214–217.
    1. Parry C.M., Hien T.T., Dougan G., White N.J., Farrar J.J., Minh H.C. TYPHOID fever is a systemic infection with the bacterium. N Engl J Med. 2002;347:1770–1782.
    1. Bhan M., Bahl R., Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005;366:749–762.
    1. Hasan R., Zafar A., Abbas Z., Mahraj V., Malik F., Zaidi A. Antibiotic resistance among Salmonella enterica serovars Typhi and Paratyphi A in Pakistan (2001–2006) J Infect Dev Ctries. 2008;2:289–294.
    1. Centers for Disease Control and Prevention Increases in heroin overdose deaths—28 States, 2010 to 2012. Morb Mortalitiy Wkly Rep. 2014;63:849–854.
    1. Fraser A., Goldberg E., Acosta C.J., Paul M., Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2007
    1. Levine M.M., Ferreccio C., Black R.E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987;1(8541):1049–1052.
    1. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 1999;17:22–27.
    1. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996;14:435–438.
    1. E. Anwar E. Goldberg A. Fraser C.J. Acosta M. Paul L. Leibovici Vaccines, for preventing typhoid fever Cochrane Database Syst Rev 2014 Jan 2 1 CD001261 10.1002/14651858.CD001261.pub3
    1. Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine. 1998;16:1391–1395.
    1. Chinnasami B., Mangayarkarasi V., Prema A., Sadasivam K., Davis M.J. Safety and Immunogenicity of Salmonella Typhi Vi conjugate vaccine (Peda TyphTM) in children upto five years. Int J Sci Res Publ. 2013;3:1–5.
    1. Jakobsen H., Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria – new potentials for conjugate vaccines? Scand J Immunol. 2003;58:119–128.
    1. Szu S.C. Development of Vi conjugate – a new generation of typhoid vaccine. Expert Rev Vacc. 2013;12:1273–1286.
    1. Thiem V.D., Lin F.Y.C., Canh D.G., Son N.H., Anh D.D., Mao N.D. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol. 2011;18:730–735.
    1. Cruz Espinoza L.M., Nichols C., Adu-Sarkodie Y., Al-Emran H.M., Baker S., Clemens J.D. Variations of invasive salmonella infections by population size in Asante Akim North Municipal. Ghana. Clin Infect Dis. 2016;62:s17–s22.
    1. Brooks W.A., Hossain A., Goswami D., Nahar K., Alam K., Ahmed N. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis. 2005;11:326–329.
    1. Group ACT Division of AIDS table for grading the severity of adult and pediatric adverse events. Allergy Infect Dis Div AIDS. 2004:1–21.
    1. Szu S.C., Hunt S., Xie G., Robbins J.B., Schneerson R., Gupta R.K. A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned. Vaccine. 2013;31:1970–1974.
    1. Jang M.S., Sahastrabuddhe S., Yun C.H., Han S.H., Yang J.S. Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method. Microb Pathog. 2016;97:19–26.
    1. Mitra M., Shah N., Ghosh A., Chatterjee S., Kaur I., Bhattacharya N. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyphTM) in Indian children: school based cluster randomized study. Hum Vaccines Immunother. 2016;12:939–945.
    1. An S.J., Yoon Y.K., Kothari S., Kim D.R., Kim J.A., Kothari N. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine. Vaccine. 2012;30:1023–1028.
    1. van Damme P., Kafeja F., Anemona A., Basile V., Hilbert A.K., de Coster I. Safety, immunogenicity and dose ranging of a new VI-CRM 197 conjugate vaccine against typhoid fever: Randomized clinical testing in healthy adults. PLoS One. 2011;6:1–7.
    1. Accelerating the control and prevention of enteric fever an invasive non-typhoidal salmonella. In: Proceedings of the 8th international conference on typhoid fever and other invasive salmonelloses Dhaka, Bangladesh, 1–2 March 2013. .
    1. Canh D.G., Lin F.Y., Thiem V.D., Trach D.D., Trong N.D., Mao N.D. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun. 2004;72:6586–6588.
    1. Tontini M., Berti F., Romano M.R., Proietti D., Zambonelli C., Bottomley M.J. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines. Vaccine. 2013;31:4827–4833.
    1. Mohan V.K., Varanasi V., Singh A., Pasetti M.F., Levine M.M., Venkatesan R. Safety and Immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61:393–402.
    1. Clemens J.D., Stanton B.F., Chakraborty J., Sack D.A., Khan M., Huda S. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis. 1987;155:79–85.
    1. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K., Harakeh H.S., Dykes J.K. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clin Diagnos Lab Immunol. 1997;4:156–167.
    1. Pulickal A.S., Gautam S., Clutterbuck E.A., Thorson S., Basynat B., Adhikari N. Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal. Clin Vacc Immunol. 2009;16:1413–1419.
    1. Kantele Anu, Pakkanen Sari H., Karttunen Riitta, Kantele Jussi M. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines–a randomized trial. PLoS One. 2013;8:e60583.
    1. Feasey Nicholas A., Levine Myron M. Typhoid vaccine development with a human challenge model. Lancet. 2017;390:2419–2421.
    1. Darton T.C., Jones C., Blohmke C.J., Waddington C.S., Zhou L., Peters A. Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a. PLoS Negl Trop Dis. 2016;10:e0004926.
    1. Juel Helene B., Thomaides-Brears Helena B., Darton Thomas C., Jones Claire, Jones Elizabeth, Shrestha Sonu. Salmonella Typhi bactericidal antibodies reduce disease severity but do not protect against typhoid fever in a controlled human infection model. Front Immunol. 1916;2018:8.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever